OTCMKTS:INTI Inhibitor Therapeutics (INTI) Stock Price, News & Analysis $0.08 0.00 (0.00%) As of 11/3/2026 02:25 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Inhibitor Therapeutics Stock (OTCMKTS:INTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inhibitor Therapeutics alerts:Sign Up Key Stats Today's Range$0.06▼$0.0850-Day Range$0.06▼$0.1152-Week Range$0.04▼$0.12Volume1,500 shsAverage Volume10,473 shsMarket Capitalization$13.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) is a clinical-stage pharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s approach has centered on evaluating established compounds for potential use in oncology. Its primary development program has involved itraconazole, an antifungal medication that is being investigated for potential anticancer applications. Inhibitor Therapeutics has studied itraconazole in connection with cancers including prostate cancer and non-small cell lung cancer. These uses remain investigational and are distinct from the drug’s approved antifungal indications. The company’s activities have primarily consisted of pharmaceutical research, clinical development and efforts to advance its oncology candidates toward potential regulatory approval. Publicly available information about its commercial operations, geographic reach and current leadership is limited.AI Generated. May Contain Errors. Read More Receive INTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INTI Stock News HeadlinesInhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual MeetingSeptember 8, 2026 | globenewswire.comCheckpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsightAugust 19, 2026 | finance.yahoo.comThe government is buying stocksDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 5 at 1:00 AM | Porter & Company (Ad)Blacksmith Medicines Announces Publication in Journal of Medicinal Chemistry Highlighting Discovery of a Non-Hydroxamate LpxC InhibitorAugust 5, 2026 | finance.yahoo.comInhibitor Therapeutics Advances Gorlin Syndrome Itraconazole ProgramJune 18, 2026 | theglobeandmail.comInhibitor Therapeutics Sues Investor Over Failed Financing DealApril 1, 2026 | tipranks.comInhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin SyndromeMarch 31, 2026 | markets.businessinsider.comInhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin SyndromeMarch 31, 2026 | globenewswire.comSee More Headlines INTI Stock Analysis - Frequently Asked Questions How have INTI shares performed this year? Inhibitor Therapeutics' stock was trading at $0.0450 at the beginning of 2026. Since then, INTI stock has increased by 75.6% and is now trading at $0.0790. How were Inhibitor Therapeutics' earnings last quarter? Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) announced its quarterly earnings results on Wednesday, March, 25th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of Inhibitor Therapeutics? Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/25/2026Today11/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:INTI CIK1042418 Webwww.inhibitortx.com Phone(888) 841-6811Fax813-527-0500Employees1Year Founded1992Profitability EPS (Trailing Twelve Months)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.30 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-171.44% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-7.90Miscellaneous Outstanding Shares173,790,000Free Float125,478,000Market Cap$13.73 million OptionableNot Optionable Beta-0.73 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:INTI) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our Partners$250,000/Month- How You Can Learn from President TrumpPresident Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get a...The Oxford Club | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredTrump compared today's market to 1929 not once but twicePresident Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredVWAV Is Turning Up the Heat in Defense Tech!VisionWave Holdings (NASDAQ: VWAV) just landed a purchase order for 200 STRATUM VARAN unmanned ground vehicles...Equiscreen | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INTI Stock Alerts